These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35543015)

  • 1. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
    Dülgar Ö; Öven BB; Atcı MM; Arıkan R; Ay S; Ayhan M; Selvi O; Ozyukseler DT; Bayram E; Özcan E; Yasin Aİ; Gümüş M
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):773-780. PubMed ID: 35543015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
    Taşçı EŞ; Kutlu Y; Ölmez ÖF; Mutlu AU; Gündoğdu Y; Seyyar M; Şahin E; Çabuk D; Majidova N; Uğurlu İ; Demirci A; Aydın D; Çavdar E; Bayram S; Yıldırım N; Karataş F; Eryılmaz MK; Çağlayan D; Menekşe S; Kut E; Arak H; Keser M; Sunar V; Perkin P; Şakalar T; Oyan B; Sönmez Ö; Özer L; Yıldız İ
    Expert Opin Pharmacother; 2024 Mar; 25(4):477-484. PubMed ID: 38568074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Prognosis of Minimal Residual Disease According to Breast Cancer Subtype in Patients with Breast or Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy.
    Go J; Ahn JH; Park JM; Choi SB; Kim JY; Park HS; Kim SI; Park BW; Park S
    Ann Surg Oncol; 2023 Nov; 30(12):7060-7068. PubMed ID: 37537485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Capecitabine after Neoadjuvant Chemotherapy in Triple Negative Breast Cancer with Lymph Node Metastasis.
    Oner I; Turkel A; Karacin C; Seyran E; Tolunay Br PK; Cakmak Oksuzoglu OB
    J Coll Physicians Surg Pak; 2023 Sep; 33(9):1012-1018. PubMed ID: 37691363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
    Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I-III Breast Cancer.
    Laws A; Pastorello R; Dey T; Grossmith S; King C; McGrath M; Schnitt SJ; Mittendorf EA; King T
    Ann Surg Oncol; 2022 Nov; 29(12):7726-7736. PubMed ID: 35810224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    Masuda N; Lee SJ; Ohtani S; Im YH; Lee ES; Yokota I; Kuroi K; Im SA; Park BW; Kim SB; Yanagita Y; Ohno S; Takao S; Aogi K; Iwata H; Jeong J; Kim A; Park KH; Sasano H; Ohashi Y; Toi M
    N Engl J Med; 2017 Jun; 376(22):2147-2159. PubMed ID: 28564564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Presenting Stage on Overall Survival in Patients Treated with Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
    Carroll JF; Hoskin TL; Leon-Ferre RA; Boughey JC
    Ann Surg Oncol; 2024 Aug; 31(8):5132-5140. PubMed ID: 38872043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
    Mayer IA; Zhao F; Arteaga CL; Symmans WF; Park BH; Burnette BL; Tevaarwerk AJ; Garcia SF; Smith KL; Makower DF; Block M; Morley KA; Jani CR; Mescher C; Dewani SJ; Tawfik B; Flaum LE; Mayer EL; Sikov WM; Rodler ET; Wagner LI; DeMichele AM; Sparano JA; Wolff AC; Miller KD
    J Clin Oncol; 2021 Aug; 39(23):2539-2551. PubMed ID: 34092112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
    van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S
    Eur J Cancer; 2022 May; 166():185-201. PubMed ID: 35305453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis.
    Bianco N; Palazzo A; Pagan E; Bagnardi V; Milano M; De Maio AP; Colleoni M
    Breast; 2021 Oct; 59():351-357. PubMed ID: 34407499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial.
    Rogers C; Cobb AN; Lloren JIC; Chaudhary LN; Johnson MK; Huang CC; Teshome M; Kong AL; Singh P; Cortina CS
    Breast Cancer Res Treat; 2024 Jan; 203(2):317-328. PubMed ID: 37864105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
    Beyerlin K; Jimenez R; Zangardi M; Fell GG; Edmonds C; Johnson A; Bossuyt V; Specht M; Mulvey TM; Moy B; Ellisen LW; Isakoff SJ; Bardia A; Spring LM
    J Oncol Pharm Pract; 2021 Dec; 27(8):1883-1890. PubMed ID: 33153384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy.
    Hasegawa Y; Matsubara N; Kogawa T; Naito Y; Harano K; Hosono A; Onishi T; Hojo T; Shimokawa M; Mukohara T
    In Vivo; 2021; 35(2):1041-1049. PubMed ID: 33622900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical Significance of the Curative Effect after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer-Correlation to Prognosis].
    Haku E; Kojima Y; Sakamaki K; Kitajima M; Takishita M; Sakamoto N; Tazou M; Nakano M; Kuroda T; Yoshie R; Tsuruga T; Shimo A; Shimo A; Motoyoshi A; Kawamoto H; Fukuda M; Tsugawa K
    Gan To Kagaku Ryoho; 2020 Oct; 47(10):1449-1455. PubMed ID: 33130739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.